bioRxivNeurosciencePreprint
Unscheduled DNA synthesis reveals a DNA repair hotspot and biomarker of somatic instability at the expanded-CAG repeat tract in the huntingtin gene
Judith Praena Fernandez, Annette GärtneriD, Jesús Pérez‐PéreziD, Sarah A. CummingiD, Jia FengiD, Katherine Van Belois, Kangning He, Denny Yang, Carla Castells-Esteve, Maria Bergé-Gardeñes, A.L. Bergander, Krzysztof P. Lubieniecki, Mihai MiclăușiD, Nicolás FissoloiD, Manuel ComabellaiD, Alexander Vogt, Lukas GebaueriD, Fatima Cavaleri, Christin Voelkner, Anastasia IllarionovaiD, Hinal Limbani, Gina MarkeiD, Richard Z. CheniD, Brinda C. PrasadiD, Thomas VogtiD, , Paolo Beuzer
- Citations
- 0
Abstract
Somatic instability (SI) of expanded DNA repeats is a hallmark of repeat expansion disorder (REDs) and drives onset and progression in Huntingtons disease (HD) yet the absence of target engagement (TE) biomarkers for SI-modulating therapies represents a critical gap to clinical development. Here, we describe the development of the unscheduled repair synthesis assay (URSA)--combining 5-ethynyl-2-deoxyuridine (EdU) pulse-labeling with digital PCR or sequencing--and show that the CAG-expanded huntingtin (HTT) exon 1 allele is a highly active DNA repair hotspot in cells from people with HD (PwHD). Repair activity increases with repeat length, is allele-specific, and depends strongly on MSH3, a central driver of somatic expansion. URSA robustly quantifies MSH3 modulation in preclinical models within days compared to weeks or months required by conventional repeat-length measurements. Critically, substantial repair activity is detectable in peripheral blood mononuclear cells (PBMCs) from PwHD, where signal correlates with CAG length and improves predictive models of somatic expansion (SE) beyond age and CAG length alone. Unlike repeat-length changes, which require years to accumulate in blood, URSA signal is measurable within days. These findings establish DNA repair activity at the mutant HTT locus as a mechanistically grounded pharmacodynamic biomarker, enabling TE monitoring on a clinically actionable timescale, and with broad applicability to REDs and other diseases where modulation of the DNA damage response is therapeutically targeted.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease
Sarah G. Aldous, Edward J. Smith, … Gillian P. Bates·BrainPeer-reviewed·Feb 21, 2024
- Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease reveal shared and tissue-specific effects
Jong‐Min Lee, Zachariah L. McLean, … Richard H. Myers·bioRxiv·Jun 10, 2024
- Identification of genetic modifiers of Huntington's disease somatic CAG repeat instability by in vivo CRISPR-Cas9 genome editing
Ricardo Mouro Pinto, Ryan Murtha, … Vanessa Chantal Wheeler·Nature GeneticsPeer-reviewed·Jan 22, 2025
- Therapeutic validation of MMR-associated genetic modifiers in a human ex vivo model of Huntington's disease
Ross Ferguson, Robert Goold, … Sarah J. Tabrizi·bioRxiv·Dec 5, 2023
- Genetic or pharmacological disruption of the MSH3 Y245/K246 IDL binding pocket slows CAG repeat expansion
Rob Goold, Jasmine Donaldson, … Sarah J. Tabrizi·NAR Molecular MedicinePeer-reviewed·Mar 30, 2026
- PMS1 as a target for splice modulation to prevent somatic CAG repeat expansion in Huntington's disease
Zachariah L. McLean, Dadi Gao, … James F. Gusella·Nature CommunicationsPeer-reviewed·Apr 12, 2024